Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study

Silvia P. Corona; Fabiola Giudici; Guy Jerusalem; Eva Ciruelos; Carla Strina; Marianna Sirico; Ottavia Bernocchi; Manuela Milani; Martina Dester; Nicoletta Ziglioli; Giuseppina Barbieri; Valeria Cervoni; Filippo Montemurro; Daniele Generali

doi:10.18632/oncotarget.28317

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study

PDF | How to cite

Oncotarget. 2022; 13:1307-1307. https://doi.org/10.18632/oncotarget.28317

Metrics: PDF 551 views | ?

Silvia P. Corona¹, Fabiola Giudici^1,2, Guy Jerusalem³, Eva Ciruelos⁴, Carla Strina⁵, Marianna Sirico⁶, Ottavia Bernocchi¹, Manuela Milani⁵, Martina Dester⁵, Nicoletta Ziglioli⁵, Giuseppina Barbieri⁵, Valeria Cervoni⁵, Filippo Montemurro⁷ and Daniele Generali^1,5

¹Department of Medicine, Surgery and Health Sciences, University of Trieste, Cattinara Hospital, Trieste, Italy
²Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy
³CHU Sart Tilman Liège and Liège University, Liège, Belgium
⁴Hospital Universitario 12 de Octubre, Madrid, Spain
⁵Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy
⁶Università Cattolica del Sacro Cuore, Roma, Italy
⁷Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

Published: December 06, 2022

Copyright: © 2022 Corona et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Written informed consent was obtained from all patients. The study protocol was approved by an independent ethics committee or institutional review board at each site.

Original article: Oncotarget. 2020; 11:2172–2181. DOI: https://doi.org/10.18632/oncotarget.27612

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28317

Publication Alerts

Post-Publication Promotion

Addendum:

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study